Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2022-11-03 Earnings Release
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore meddelar nya resultat från IPF studien AIR som ytterligare stärker nytta-riskprofilen hos C21
Earnings Release Classification · 95% confidence The document is a press release dated November 3, 2022, announcing new results from the ongoing Phase 2a AIR study for IPF treatment (C21). It details clinical findings (stabilization of disease, increase in FVC), mentions an upcoming web broadcast to present the information, and discusses future development plans. The concluding paragraph states: "Denna information är sådan som Vicore Pharma Holding AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This structure—announcing key results and regulatory obligations—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on the release of specific, periodic financial/clinical performance data (interim analysis results) rather than a full annual report (10-K) or a comprehensive quarterly report (IR), 'ER' (Earnings Release) is the most appropriate fit for announcing key performance indicators and study outcomes. It is not a transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA), as it contains substantial analysis and results. FY 2022
2022-11-03 Swedish
Delårsrapport juli-september 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB for the period 1 July to 30 September 2022. It contains comprehensive financial statements, management commentary (VD-ord), business area descriptions, and a pipeline overview. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-03 Swedish
Interim report July-September 2022
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for the period Jul 1-Sep 30, 2022, for Vicore Pharma Holding AB. It contains comprehensive financial statements (Group and Parent company), notes, key performance measures, and an auditor's review report. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2022
2022-11-03 English
Vicore offentliggör valberedningen inför årsstämman 2023
Board/Management Information Classification · 99% confidence The document is titled "Vicore offentliggör valberedningen inför årsstämman 2023" (Vicore announces the nomination committee for the 2023 Annual General Meeting). It details the composition of the nomination committee, its tasks (proposing board members, remuneration, etc.), and the deadline for shareholder input regarding the upcoming AGM on May 11, 2023. This content directly relates to the preparation and governance surrounding the Annual General Meeting (AGM). While it is an announcement about the AGM process, the specific focus on the 'valberedning' (nomination committee) composition and function aligns most closely with governance and meeting preparation materials. Since there is no specific code for 'Nomination Committee Announcement', and it is directly tied to the AGM, AGM-R (AGM Information) is the most appropriate classification, as these materials are typically presented or discussed at the AGM. It is not a DEF 14A (Remuneration) or a general Governance Report (CGR), but a specific procedural step for the AGM.
2022-10-20 Swedish
Vicore announces the Nomination Committee for the 2023 Annual General Meeting
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of the Nomination Committee for the upcoming 2023 Annual General Meeting (AGM). It details the members appointed by major shareholders and outlines the committee's tasks related to board elections and fees for the AGM. This content directly relates to the preparatory steps and governance surrounding the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-10-20 English
Vicore ger en uppdatering av ATTRACT-3 studien i COVID-19
Earnings Release Classification · 95% confidence The document is a press release from Vicore Pharma Holding AB dated September 15, 2022, announcing 'top-line' results from the ATTRACT-3 Phase 3 study regarding their drug C21 for COVID-19. It details that the primary endpoint was not met and announces the discontinuation of C21 development for COVID-19, while pivoting focus to IPF and PAH. The text concludes with a statement that this information is required to be made public under the EU Market Abuse Regulation, which strongly suggests a regulatory disclosure. Since it is an initial announcement of periodical financial/trial results (top-line data) rather than a comprehensive report (like 10-K or IR), the most appropriate classification is 'Earnings Release' (ER), as this category often encompasses initial trial outcome announcements for clinical-stage pharma companies. It is not a full transcript (CT), a formal Annual Report (10-K), or a general regulatory filing (RNS), as ER is more specific for this type of result announcement. FY 2022
2022-09-15 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.